RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  2. Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05527470, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Patients with newly histologically confirmed non-keratinizing (according to WHO histologically type);

    Inclusion criterion 1

  3. Tumor staged as III-IVb (according to the 8th AJCC edition);

    Inclusion criterion 2

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    Inclusion criterion 8

  5. Normal complete blood count level (hemoglobin >10 g/dL, white blood cells ≥4000/μL, platelets ≥100 000/μL);

    Inclusion criterion 5

    Normal hepatic functions (serum total bilirubin ≤1.6 mg/dL, serum transminase < 2.5 times higher than upper limit);

    Inclusion criterion 6

    Normal renal function (serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min);

    Inclusion criterion 7

  6. No pregnant female;

    Inclusion criterion 3

    Pregnancy or lactation.

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05527470, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with newly histologically confirmed non-keratinizing (according to WHO histologically type);
  • Tumor staged as III-IVb (according to the 8th AJCC edition);
  • No pregnant female;
  • Age between 18-65;
  • Normal complete blood count level (hemoglobin >10 g/dL, white blood cells ≥4000/μL, platelets ≥100 000/μL);
  • Normal hepatic functions (serum total bilirubin ≤1.6 mg/dL, serum transminase < 2.5 times higher than upper limit);
  • Normal renal function (serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min);
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • Without radiotherapy or chemotherapy;
  • Patients must give signed informed consent.

Exclusion Criteria:

  • Disease progression in the process of the treatment;
  • The presence of uncontrolled life-threatening illness;
  • History of previous radiotherapy or chemotherapy;
  • Pregnancy or lactation.

Quoted from ClinicalTrials.gov, NCT05527470, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05527470, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05527470